We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

The company’s monoclonal antibody met primary endpoints in Phase IIb/III trial in infants entering their first respiratory ...

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

Interim phase 3 results showed the IL-13 monoclonal antibody improves histology and symptoms in EoE, even in participants ...

Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...